Title: Wei P, et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther. 2010 Jun;9(6):1618-28.
1962925-29-6
1262238-11-8 | Incb3344 | AA009C9M | MFCD25977164
1218777-13-9 | CAY10505 | AA009CJE | MFCD00640727
137225-34-4 | 2-(1-Chloroethyl)quinazolin-4(3h)-one | AA009CV7 | MFCD06340074
1276056-72-4 | (5-Bromo-2-chloropyridin-3-yl)methanamine hydrochloride | AA009DAH | MFCD17214184
121562-07-0 | 3-Bromo-5-isopropyl-1,2,4-oxadiazole | AA009DOC | MFCD17078865
130566-34-6 | 3-Chloro-2-(propan-2-yloxy)aniline | AA009DSH | MFCD11053905
1221722-96-8 | 1-(Trifluoromethyl)-3-azabicyclo[3.1.0]hexane Hydrochloride | AA009DWZ | MFCD15209730
125198-40-5 | Mycophenolic Acid Cyclopropane Analogue | AA009E43
129050-27-7 | (1S,2R)-2-(2-Benzylamino-1-hydroxyethyl)-6-fluorochromane | AA009EC0 | MFCD18379191
1216745-79-7 | MefenaMic-d4 Acid | AA009ELE | MFCD08063563